Chingiz Underbayev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chingiz Underbayev has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Wiestner
Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
87 shared publications - Clare Sun
Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
87 shared publications - Erika M. Gaglione
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
87 shared publications - Inhye E. Ahn
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
86 shared publications - Jonathan Chen
Case Western Reserve University, Cleveland, USA
86 shared publications - Pia Nierman
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
86 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Table S7. DEGs for 1 month Comparison of CD49d+ and CD49d-
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Table S7. DEGs for 1 month Comparison of CD49d+ and CD49d-
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Table S3: Representativeness of Study Participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Table S3: Representativeness of Study Participants
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Figure S4. Clinical impact of CD49d bimodal expression on durability of BTKi therapy.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Figure S4. Clinical impact of CD49d bimodal expression on durability of BTKi therapy.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Table S1. Baseline characteristics of acalabrutinib treated patients
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Table S1. Baseline characteristics of acalabrutinib treated patients
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Table S8. DEGs for 6 months Comparison of CD49d+ and CD49d-
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Table S8. DEGs for 6 months Comparison of CD49d+ and CD49d-
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Table S5: CD49d samples used for the RNAseq analysis
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Table S5: CD49d samples used for the RNAseq analysis
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Table S9. Gene Signatures
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Table S9. Gene Signatures
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Table S6. DEGs for Baseline Comparison of CD49d+ and CD49d
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Table S6. DEGs for Baseline Comparison of CD49d+ and CD49d
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Figure S3. In vivo effect of acalabrutinib on the VLA-4 activation upon BCR and chemokine signaling
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Figure S3. In vivo effect of acalabrutinib on the VLA-4 activation upon BCR and chemokine signaling
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Table S4. Mutations status of patients with disease progression on BTKis
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Table S4. Mutations status of patients with disease progression on BTKis